Monopar Therapeutics Inc.

As of June 30, 2026, Monopar Therapeutics Inc carries a market capitalization of 547.71M, placing it among publicly traded companies globally. Its enterprise value stands at 430.26M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Monopar Therapeutics Inc's next confirmed earnings release is scheduled for November 6, 2026.

As of June 30, 2026, Monopar Therapeutics Inc has 6.71M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Monopar Therapeutics Inc maintains a current ratio of 33.56, meaning it holds 33.6x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Monopar Therapeutics Inc posted a negative return on equity (ROE) of -19.50, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -18.90, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 20.50, a quick read on workforce productivity versus industry peers.

As of the close on October 23, 2026, Monopar Therapeutics Inc's stock has declined approximately 7.19% over the past 52 weeks. The 50-day moving average sits at 83.61, while the 200-day moving average is 67.32.

Over the twelve months ended June 30, 2026, Monopar Therapeutics Inc generated - - in revenue and converted that into -15.62M in net income, yielding earnings per share of -2.02. EBITDA reached -19.36M, while operating income came in at -19.36M.

As of June 30, 2026, Monopar Therapeutics Inc holds 117.55M in cash and equivalents against 94,382.72 in total debt, resulting in a net debt position of -46.18M. Total book value stands at 114.54M, with working capital of 114.44M providing operational flexibility.

Monopar Therapeutics Inc produced -10.66M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -1.69: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -14.57, meaning Monopar Therapeutics Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Monopar Therapeutics Inc's most recent stock split took place on August 13, 2024 with a 5:1 split ratio.

As of June 30, 2026, Monopar Therapeutics Inc has an Altman Z-Score of 90.64, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.